Richard G. Stock, MD

Richard G. Stock, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Richard G. Stock, MD, is a Professor of Radiation Oncology at Mount Sinai in New York, New York. Dr. Stock’s clinical interests include cancers of the bladder, prostate, testis, and bone. His research focuses on prostate cancer and prostate brachytherapy. Dr. Stock is best known for establishing a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies.

Dr. Stock earned his medical degree and an internship in Internal Medicine from Mount Sinai. He then completed a residency in Internal Medicine at the Beth Israel Medical Center in New York, New York. Dr. Stock then completed a residency in Radiation Oncology at the Memorial Sloan Kettering Cancer Center in New York, New York.

Dr. Stock has served on the board of American College of Radiology Testing and the American Brachytherapy Society. He also served as a guest editor of a special Brachytherapy issue of Techniques in Urology. Dr. Stock has authored and co-authored over 140 publications and has contributed substantially to the understanding of prostate brachytherapy. Dr. Stock is also a co-investigator on Department of Defense, American Cancer Society, and NIH RO1 grants to study the relationship between genetic mutations and radiation side effects for patients undergoing radiation for prostate cancer.  In a recent publication in the International Journal of Radiation Oncology Biology Physics, Dr. Stock ranked among the top 4% of academic Radiation Oncologists in terms of the h-factor, a surrogate score for research productivity.

Talks by Richard G. Stock, MD

Adaptive Radiotherapy

Adaptive Radiotherapy

| Feb 2025

In this 23-minute presentation, Richard D. Stock, MD, explores integrating artificial intelligence in radiation oncology, focusing on adaptive radiation therapy (ART). Three categories of ART—offline, online, and real-time—are detailed, explaining their respective timelines, imaging technologies, and resource requirements. The discussion critically evaluates ART in prostate cancer, where anatomical shifts due to bladder or rectal changes can influence treatment accuracy.

Examples of imaging technologies like MRI and PET scans are discussed for their contributions to ART’s precision and potential to adapt treatment based on tumor shrinkage or biological response. Comparative studies from the Netherlands and other institutions demonstrate ART’s ability to refine target margins, decrease normal tissue exposure, and predict patient outcomes more accurately.

As ART shows promise in improving treatment precision, Dr. Stock emphasizes its potential for advancing radiation oncology, driven by technological innovation and ongoing research.

Read More